SCHEMBL282078

SCHEMBL282078

CNC(=O)c1nccc(Cl)n1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.38
PLK1 P53350 1/20 0.38
KMO O15229 2/20 0.37
GAA P10253 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
RAB9A P51151 1/20 0.36
KDM4E B2RXH2 2/20 0.36
KDR P35968 1/20 0.36
PTPN11 Q06124 1/20 0.36
CASP1 P29466 1/20 0.36
NUDT1 P36639 1/20 0.35
HPGD P15428 1/20 0.35
SMARCA2 P51531 1/20 0.35
SMARCA4 P51532 1/20 0.35
ALOX15 P16050 1/20 0.35
GRM5 P41594 1/20 0.35
RIPK1 Q13546 1/20 0.35
P2RX7 Q99572 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31589417 0.81 P2RX7 (0.57) L3MBTL1KMOGAASMN1; SMN2KDM4E
SCHEMBL162373 0.79 PLK1 (0.39) PLK1GAASMN1; SMN2KDM4EKDR
SCHEMBL30210828 0.79 ALOX15 (0.41) L3MBTL1PLK1GAASMN1; SMN2RAB9A
SCHEMBL8159378 0.79 SORD (0.44) KMOSMN1; SMN2SMARCA2SMARCA4
SCHEMBL23795448 0.78 ATR (0.42) L3MBTL1KMOKDM4EALOX15
SCHEMBL2773643 0.76 KMO (0.41) KMOGAASMN1; SMN2SMARCA2SMARCA4
SCHEMBL287227 0.76 KMO (0.58) KMO
SCHEMBL31312412 0.76 S1PR2 (0.42) L3MBTL1PLK1GAASMN1; SMN2RAB9A
SCHEMBL23772028 0.75 LMNA (0.40) L3MBTL1PLK1GAASMN1; SMN2RAB9A
SCHEMBL6635914 0.75 KDR (0.44) PLK1SMN1; SMN2RAB9AKDM4EKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8957087-B2 Heterocyclic substituted acardite derivate and application thereof Jiangsu Provincial Institute of Materia Medica Co., Ltd. (CN) 2015-02-17 US disclosed
EP-2428506-B1 HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF NANJING LUYESIKE PHARMACEUTICAL CO LTD (CN) 2014-03-05 EP disclosed
EP-2428506-A1 HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF Jiangsu Provincial Institute Of Materia Medica Co. (CN) 2012-03-14 EP disclosed
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) 2012-03-01 US disclosed
CN-101372475-B Aromatic heterocyclic substituted diphenyl urea derivative and application thereof NANJING UNIVERSITY OF TECHNOLOGY 2012-01-04 CN disclosed
CN-101671301-A Heterocyclic substituent acardite derivate and application thereof JIANGSU PROVINCIAL INST OF MAT 2010-03-17 CN disclosed
CN-101372475-A Aromatic heterocyclic substituted diphenyl urea derivative and application thereof NANJING UNIVERSITY OF TECHNOLOGY (CN) 2009-02-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 L3MBTL1 3133/4885PLK1 1034/4885KMO 264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.